Department of Medical insurance, Central Hospital Affiliated to Shandong First Medical University, No. 105, Jiefang Road, Shandong Province, Jinan City, 250013, China.
Department of Clinical Laboratory, Central Hospital Affiliated to Shandong First Medical University, No. 105, Jiefang Road, Shandong Province, Jinan City, 250013, China.
Appl Biochem Biotechnol. 2023 Sep;195(9):5299-5311. doi: 10.1007/s12010-022-03949-x. Epub 2022 May 27.
Diabetic retinopathy (DR) is the key cause of blindness and visual impairment in diabetes patients around the world. The high levels of oxidative stress in diabetes patients cause diabetic retinopathy. In addition to being an antioxidant, Bergenin also works as an immunosuppressant, an anti-inflammatory, and anticarcinogenic against hepatocarcinoma. This study examined the effects of Bergenin on diabetic retinopathy rats, using Streptozotocin (STZ) intraperitoneally to induce diabetes in rats. The animals were divided into four groups (n = 6), including a normal control (Group I), diabetic control (Group II), Bergenin (25 mg/kg) (Group III), and metformin (350 mg/kg) (Group IV). As previously mentioned, each animal received treatment for 60 days. To induce DR, rats were administered STZ (60 mg/kg) intraperitoneally for 60 days. Standard methods were utilized to measure the body weight of rats, blood glucose levels. We measured lipid profiles (Triglycerides, cholesterol, LDL, and HDL), inflammatory markers, and antioxidant levels with their respective kits. Analysis of retinal tissue morphometry and MMP-9, VEGF, and MCP-1 levels in serum was performed. Our research examined the expression levels of target genes (TNF-α, IL-1β, and IL-6) using RT-PCR analysis. STZ-induced animals that were treated with Bergenin had less food intake, lower blood glucose, and improved body weight. Bergenin significantly suppressed levels of pro-inflammatory cytokines, cholesterol, TG, LDL, AI, MMP-9, VEGF, and MCP-1 and increased the level of HDL and antioxidant enzymes in STZ-induced DR rats. As well as increasing antioxidant levels, reducing retinal thickness, and increasing cell numbers, Bergenin also lessened DR remarkably. The results of this study demonstrated that Bergenin effectively inhibited STZ-induced DR in rats.
糖尿病性视网膜病变（DR）是全世界糖尿病患者失明和视力损害的主要原因。糖尿病患者体内氧化应激水平高，导致糖尿病性视网膜病变。除了作为一种抗氧化剂外，毛喉素还具有免疫抑制、抗炎和抗肝癌作用。本研究使用链脲佐菌素（STZ）腹腔内注射诱导大鼠糖尿病，观察毛喉素对糖尿病性视网膜病变大鼠的作用。将动物分为四组（n = 6），包括正常对照组（I 组）、糖尿病对照组（II 组）、毛喉素（25mg/kg）组（III 组）和二甲双胍（350mg/kg）组（IV 组）。如前所述，每组动物接受治疗 60 天。为了诱导 DR，大鼠腹腔内注射 STZ（60mg/kg）60 天。采用标准方法测量大鼠体重、血糖水平。我们使用各自的试剂盒测量血脂谱（甘油三酯、胆固醇、LDL 和 HDL）、炎症标志物和抗氧化剂水平。分析视网膜组织形态计量学和血清中 MMP-9、VEGF 和 MCP-1 水平。我们使用 RT-PCR 分析研究了目标基因（TNF-α、IL-1β 和 IL-6）的表达水平。用毛喉素治疗的 STZ 诱导动物摄食量减少、血糖降低、体重增加。毛喉素显著抑制促炎细胞因子、胆固醇、TG、LDL、AI、MMP-9、VEGF 和 MCP-1 的水平，增加 STZ 诱导的 DR 大鼠 HDL 和抗氧化酶的水平。毛喉素不仅增加抗氧化水平、减少视网膜厚度和增加细胞数量，还显著减轻 DR。本研究结果表明，毛喉素有效抑制了 STZ 诱导的大鼠 DR。
